Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

DA. Wheatley, R. Berardi, MA. Climent Duran, A. Tomiak, AP. Greystoke, AM. Joshua, HT. Arkenau, L. Géczi, JG. Corbacho, LG. Paz-Ares, SA. Hussain, L. Petruželka, A. Delmonte, C. Chappey, JC. Masters, E. Michelon, DA. Murphy, S. Mwewa, R. Cesari,...

. 2024 ; 4 (6) : 1609-1619. [pub] 20240628

Language English Country United States

Document type Journal Article, Clinical Trial, Phase I, Clinical Trial, Phase II, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24013435

Grant support
Pfizer (Davis)
Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945)

PURPOSE: Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase Ib/II JAVELIN Chemotherapy Medley trial (NCT03317496) evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Avelumab 800 or 1,200 mg was administered continuously every 3 weeks with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC. Dual primary endpoints were dose-limiting toxicity (DLT; phase Ib) and confirmed objective response (phase Ib/II). RESULTS: In phase Ib, urothelial carcinoma and NSCLC cohorts received avelumab 800 mg (n = 13 and n = 6, respectively) or 1,200 mg (n = 6 each) + chemotherapy. In evaluable patients with urothelial carcinoma treated with avelumab 800 or 1,200 mg + chemotherapy, DLT occurred in 1/12 (8.3%) and 1/6 (16.7%), respectively; no DLT occurred in the NSCLC cohort. In phase II, 35 additional patients with urothelial carcinoma received avelumab 1,200 mg + chemotherapy. Across all treated patients, safety profiles were similar irrespective of avelumab dose. Objective response rates (95% confidence internal) with avelumab 800 or 1,200 mg + chemotherapy, respectively, across phase Ib/II, were 53.8% (25.1-80.8) and 39.0% (24.2-55.5) in urothelial carcinoma, and 50.0% (11.8-88.2) and 33.3% (4.3-77.7) in NSCLC. CONCLUSIONS: Preliminary efficacy and safety findings with avelumab + chemotherapy in urothelial carcinoma and NSCLC were consistent with previous studies of similar combination regimens. Conclusions about clinical activity are limited by small patient numbers. SIGNIFICANCE: This phase Ib/II trial evaluated avelumab (immune checkpoint inhibitor) administered concurrently with standard first-line chemotherapy in patients with advanced urothelial carcinoma or advanced nonsquamous NSCLC without actionable mutations. Efficacy and safety appeared consistent with previous studies of similar combinations, although patient numbers were small.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013435
003      
CZ-PrNML
005      
20240905134418.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/2767-9764.CRC-23-0459 $2 doi
035    __
$a (PubMed)38669053
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wheatley, Duncan A $u Royal Cornwall Hospital, Treliske, Truro, United Kingdom $1 https://orcid.org/0000000219195114
245    10
$a First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study / $c DA. Wheatley, R. Berardi, MA. Climent Duran, A. Tomiak, AP. Greystoke, AM. Joshua, HT. Arkenau, L. Géczi, JG. Corbacho, LG. Paz-Ares, SA. Hussain, L. Petruželka, A. Delmonte, C. Chappey, JC. Masters, E. Michelon, DA. Murphy, S. Mwewa, R. Cesari, B. Doger de Spéville
520    9_
$a PURPOSE: Chemotherapy can potentially enhance the activity of immune checkpoint inhibitors by promoting immune priming. The phase Ib/II JAVELIN Chemotherapy Medley trial (NCT03317496) evaluated first-line avelumab + concurrent chemotherapy in patients with advanced urothelial carcinoma or non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Avelumab 800 or 1,200 mg was administered continuously every 3 weeks with standard doses of cisplatin + gemcitabine in patients with urothelial carcinoma, or carboplatin + pemetrexed in patients with nonsquamous NSCLC. Dual primary endpoints were dose-limiting toxicity (DLT; phase Ib) and confirmed objective response (phase Ib/II). RESULTS: In phase Ib, urothelial carcinoma and NSCLC cohorts received avelumab 800 mg (n = 13 and n = 6, respectively) or 1,200 mg (n = 6 each) + chemotherapy. In evaluable patients with urothelial carcinoma treated with avelumab 800 or 1,200 mg + chemotherapy, DLT occurred in 1/12 (8.3%) and 1/6 (16.7%), respectively; no DLT occurred in the NSCLC cohort. In phase II, 35 additional patients with urothelial carcinoma received avelumab 1,200 mg + chemotherapy. Across all treated patients, safety profiles were similar irrespective of avelumab dose. Objective response rates (95% confidence internal) with avelumab 800 or 1,200 mg + chemotherapy, respectively, across phase Ib/II, were 53.8% (25.1-80.8) and 39.0% (24.2-55.5) in urothelial carcinoma, and 50.0% (11.8-88.2) and 33.3% (4.3-77.7) in NSCLC. CONCLUSIONS: Preliminary efficacy and safety findings with avelumab + chemotherapy in urothelial carcinoma and NSCLC were consistent with previous studies of similar combination regimens. Conclusions about clinical activity are limited by small patient numbers. SIGNIFICANCE: This phase Ib/II trial evaluated avelumab (immune checkpoint inhibitor) administered concurrently with standard first-line chemotherapy in patients with advanced urothelial carcinoma or advanced nonsquamous NSCLC without actionable mutations. Efficacy and safety appeared consistent with previous studies of similar combinations, although patient numbers were small.
650    _2
$a lidé $7 D006801
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a senioři $7 D000368
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $x aplikace a dávkování $7 D000971
650    12
$a nemalobuněčný karcinom plic $x farmakoterapie $x patologie $7 D002289
650    12
$a nádory plic $x farmakoterapie $x patologie $7 D008175
650    _2
$a karboplatina $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D016190
650    _2
$a gemcitabin $7 D000093542
650    _2
$a deoxycytidin $x analogy a deriváty $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D003841
650    _2
$a cisplatina $x aplikace a dávkování $x terapeutické užití $x škodlivé účinky $7 D002945
650    _2
$a pemetrexed $x terapeutické užití $x aplikace a dávkování $x škodlivé účinky $7 D000068437
650    _2
$a dospělí $7 D000328
650    _2
$a karcinom z přechodných buněk $x farmakoterapie $x patologie $7 D002295
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a urologické nádory $x farmakoterapie $x patologie $7 D014571
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze I $7 D017426
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Berardi, Rossana $u AOU delle Marche, Università Politecnica delle Marche, Ancona, Italy $1 https://orcid.org/0000000295292960
700    1_
$a Climent Duran, Miguel A $u Instituto Valenciano de Oncología, Valencia, Spain $1 https://orcid.org/0000000175230212
700    1_
$a Tomiak, Anna $u Kingston Health Sciences Centre, Kingston, Ontario, Canada $1 https://orcid.org/0000000197552474
700    1_
$a Greystoke, Alastair P $u NU Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom $1 https://orcid.org/0000000191680387
700    1_
$a Joshua, Anthony M $u St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia $1 https://orcid.org/0000000151594580
700    1_
$a Arkenau, Hendrik-Tobias $u Sarah Cannon Research Institute, HCA Healthcare, London, United Kingdom $1 https://orcid.org/0000000220151549
700    1_
$a Géczi, Lajos $u National Institute of Oncology, Budapest, Hungary $1 https://orcid.org/0009000295380829
700    1_
$a Corbacho, Javier Garciá $u Clinic Institute of Hematological and Oncological Diseases, Hospital Clinic, Barcelona, Spain $1 https://orcid.org/0000000261098449
700    1_
$a Paz-Ares, Luis G $u Hospital Universitario 12 de Octubre, Madrid, Spain $1 https://orcid.org/0000000219473364
700    1_
$a Hussain, Syed A $u Weston Park Hospital, University of Sheffield, Sheffield, United Kingdom $1 https://orcid.org/000000031552511X
700    1_
$a Petruželka, Lubos $u General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Delmonte, Angelo $u IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori," Meldola, Italy $1 https://orcid.org/0009000426298519
700    1_
$a Chappey, Colombe $u Pfizer, San Francisco, California $1 https://orcid.org/0009000336233383
700    1_
$a Masters, Joanna C $u Pfizer, San Diego, California $1 https://orcid.org/000000022492764X
700    1_
$a Michelon, Elisabete $u Pfizer, New York, New York $1 https://orcid.org/0009000583623717
700    1_
$a Murphy, Danielle A $u Pfizer, San Diego, California $1 https://orcid.org/0000000314489444
700    1_
$a Mwewa, Sandrine $u Pfizer, Paris, France $1 https://orcid.org/0009000863741195
700    1_
$a Cesari, Rossano $u Pfizer, Milan, Italy $1 https://orcid.org/0009000837573220
700    1_
$a Doger de Spéville, Bernard $u Fundación Jiménez Díaz University Hospital, Madrid, Spain $1 https://orcid.org/0009000432645433
773    0_
$w MED00215133 $t Cancer research communications. $x 2767-9764 $g Roč. 4, č. 6 (2024), s. 1609-1619
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38669053 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134412 $b ABA008
999    __
$a ok $b bmc $g 2143328 $s 1225301
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 4 $c 6 $d 1609-1619 $e 20240628 $i 2767-9764 $m Cancer research communications. $n Cancer Res Commun $x MED00215133
GRA    __
$p Pfizer (Davis)
GRA    __
$p Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945)
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options